Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney.
Evidence suggests that Angiotensin II plays an important role in the complex process of renal organogenesis. Rat kidney organogenesis starts between E13-14 and lasts up to 2 weeks after birth. The present study demonstrates histologic modifications and changes in receptor localisation in animals born from mothers treated with Angiotensin II, Losartan or PD123319 (1.0 mg/kg/day) during late pregnancy. Angiotensin II-treated animals exhibited very well developed tubules in the renal medulla in coincidence with higher AT(1) binding. Control animals exhibited angiotensin AT(2) binding in the outer stripe of the outer medulla, while in the Angiotensin II-treated animals binding was observed to the inner stripe. In Angiotensin II-treated 1-week-old animals, the nephrogenic zone contained fewer immature structures, and more developed collecting tubules than control animals. Treatment with Losartan resulted in severe renal abnormalities. For newborn and 1-week-old animals, glomeruli exhibited altered shape and enlarged Bowman spaces, in concordance with a loss of [(125)I]Angiotensin II binding in the cortex. Blockade with PD123319 led to an enlarged nephrogenic zone with increased number of immature glomeruli, and less glomeruli in the juxtamedullary area. Autoradiography showed a considerable loss of AT(1) binding in the kidney cortex of PD123319-treated animals at both ages. The present results show for the first time histomorphological and receptor localisation alterations following treatment with low doses of Losartan and PD123319 during pregnancy. These observations confirm previous assumptions that in the developing kidney Angiotensin II exerts stimulatory effects through AT(1) receptors that might be counterbalanced by angiotensin AT(2) receptors.
Sánchez
Susana I
SI
Instituto Multidisciplinario de Investigaciones Biológicas (IMIBIO-CONICET), Facultad de Química, Bioquímica y Farmacia. - Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina.
Seltzer
Alicia M
AM
Fuentes
Lucia B
LB
Forneris
Myriam L
ML
Ciuffo
Gladys M
GM
D000014:Abnormalities, Drug-Induced / Q000473:pathology*; D000375:Aging / Q000378:metabolism; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000494:pharmacology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000633:toxicity*; D057912:Angiotensin II Type 2 Receptor Blockers; D000818:Animals; D000831:Animals, Newborn; D001345:Autoradiography; D005260:Female; D007093:Imidazoles / Q000633:toxicity; D007668:Kidney / Q000002:abnormalities* / Q000473:pathology; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology; D019808:Losartan / Q000633:toxicity; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000502:physiology*; D011725:Pyridines / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D044139:Receptor, Angiotensin, Type 2 / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D057912:Angiotensin II Type 2 Receptor Blockers; D007093:Imidazoles; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II; C073402:PD 123319; D019808:Losartan